Towards selective CNS PET Imaging of the 5-HT7 Receptor System: Past, Present and Future

Research output: Contribution to journal › Review › Research › peer-review

Standard

Towards selective CNS PET Imaging of the 5-HT7 Receptor System : Past, Present and Future. / L'Estrade, Elina T; Erlandsson, Maria; Edgar, Fraser G; Ohlsson, Tomas; Knudsen, Gitte M; Herth, Matthias M.

In: Neuropharmacology, Vol. 172, 107830, 2020.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

L'Estrade, ET, Erlandsson, M, Edgar, FG, Ohlsson, T, Knudsen, GM & Herth, MM 2020, 'Towards selective CNS PET Imaging of the 5-HT7 Receptor System: Past, Present and Future', Neuropharmacology, vol. 172, 107830. https://doi.org/10.1016/j.neuropharm.2019.107830

APA

L'Estrade, E. T., Erlandsson, M., Edgar, F. G., Ohlsson, T., Knudsen, G. M., & Herth, M. M. (2020). Towards selective CNS PET Imaging of the 5-HT7 Receptor System: Past, Present and Future. Neuropharmacology, 172, [107830]. https://doi.org/10.1016/j.neuropharm.2019.107830

Vancouver

L'Estrade ET, Erlandsson M, Edgar FG, Ohlsson T, Knudsen GM, Herth MM. Towards selective CNS PET Imaging of the 5-HT7 Receptor System: Past, Present and Future. Neuropharmacology. 2020;172. 107830. https://doi.org/10.1016/j.neuropharm.2019.107830

Author

L'Estrade, Elina T ; Erlandsson, Maria ; Edgar, Fraser G ; Ohlsson, Tomas ; Knudsen, Gitte M ; Herth, Matthias M. / Towards selective CNS PET Imaging of the 5-HT7 Receptor System : Past, Present and Future. In: Neuropharmacology. 2020 ; Vol. 172.

Bibtex

@article{35cd09898405447e9d7aee213d3817a9,
title = "Towards selective CNS PET Imaging of the 5-HT7 Receptor System: Past, Present and Future",
abstract = "Since its discovery in 1993, the serotonin receptor subtype 7 (5-HT7) has attracted significant attention as a potential drug target; due to its elucidated roles in conditions such as insomnia, schizophrenia, and more. Therefore, it is unsurprising that there has been relatively early efforts undertaken to develop a positron emission tomography (PET) imaging agent for said receptor system. PET can be clinically used to probe receptor systems in vivo, permitting information such as a drug's occupancy against this system to be investigated. This review focuses on the efforts towards the development of a 5-HT7R selective PET CNS tracer over the last 20 years, critically reflecting on applied strategies and commonly employed chemical frameworks and suggests future considerations that are needed to successfully develop a PET tracer for this clinically relevant target.",
author = "L'Estrade, {Elina T} and Maria Erlandsson and Edgar, {Fraser G} and Tomas Ohlsson and Knudsen, {Gitte M} and Herth, {Matthias M}",
note = "Copyright {\textcopyright} 2019. Published by Elsevier Ltd.",
year = "2020",
doi = "10.1016/j.neuropharm.2019.107830",
language = "English",
volume = "172",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - Towards selective CNS PET Imaging of the 5-HT7 Receptor System

T2 - Past, Present and Future

AU - L'Estrade, Elina T

AU - Erlandsson, Maria

AU - Edgar, Fraser G

AU - Ohlsson, Tomas

AU - Knudsen, Gitte M

AU - Herth, Matthias M

N1 - Copyright © 2019. Published by Elsevier Ltd.

PY - 2020

Y1 - 2020

N2 - Since its discovery in 1993, the serotonin receptor subtype 7 (5-HT7) has attracted significant attention as a potential drug target; due to its elucidated roles in conditions such as insomnia, schizophrenia, and more. Therefore, it is unsurprising that there has been relatively early efforts undertaken to develop a positron emission tomography (PET) imaging agent for said receptor system. PET can be clinically used to probe receptor systems in vivo, permitting information such as a drug's occupancy against this system to be investigated. This review focuses on the efforts towards the development of a 5-HT7R selective PET CNS tracer over the last 20 years, critically reflecting on applied strategies and commonly employed chemical frameworks and suggests future considerations that are needed to successfully develop a PET tracer for this clinically relevant target.

AB - Since its discovery in 1993, the serotonin receptor subtype 7 (5-HT7) has attracted significant attention as a potential drug target; due to its elucidated roles in conditions such as insomnia, schizophrenia, and more. Therefore, it is unsurprising that there has been relatively early efforts undertaken to develop a positron emission tomography (PET) imaging agent for said receptor system. PET can be clinically used to probe receptor systems in vivo, permitting information such as a drug's occupancy against this system to be investigated. This review focuses on the efforts towards the development of a 5-HT7R selective PET CNS tracer over the last 20 years, critically reflecting on applied strategies and commonly employed chemical frameworks and suggests future considerations that are needed to successfully develop a PET tracer for this clinically relevant target.

U2 - 10.1016/j.neuropharm.2019.107830

DO - 10.1016/j.neuropharm.2019.107830

M3 - Review

C2 - 31669129

VL - 172

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

M1 - 107830

ER -

ID: 231253285